Johan W. Molling

1.2k total citations
14 papers, 936 citations indexed

About

Johan W. Molling is a scholar working on Immunology, Oncology and Virology. According to data from OpenAlex, Johan W. Molling has authored 14 papers receiving a total of 936 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 6 papers in Oncology and 2 papers in Virology. Recurrent topics in Johan W. Molling's work include Immune Cell Function and Interaction (12 papers), T-cell and B-cell Immunology (8 papers) and CAR-T cell therapy research (6 papers). Johan W. Molling is often cited by papers focused on Immune Cell Function and Interaction (12 papers), T-cell and B-cell Immunology (8 papers) and CAR-T cell therapy research (6 papers). Johan W. Molling collaborates with scholars based in Netherlands, Japan and India. Johan W. Molling's co-authors include Rik J. Scheper, Alfons J.M. van den Eertwegh, B. Mary E. von Blomberg, Hans van Vliet, Hetty J. Bontkes, Wendy Kölgen, Johannes A. Langendijk, C. René Leemans, Marı́a Moreno and Nobusuke Nishi and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and International Journal of Cancer.

In The Last Decade

Johan W. Molling

14 papers receiving 925 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johan W. Molling Netherlands 12 805 398 122 88 39 14 936
Christopher J. Chan Australia 10 1.0k 1.3× 482 1.2× 61 0.5× 126 1.4× 31 0.8× 12 1.2k
Chun‐Jen J. Chen New Zealand 11 936 1.2× 283 0.7× 75 0.6× 256 2.9× 28 0.7× 15 1.1k
Thamara Beyer Germany 8 615 0.8× 205 0.5× 57 0.5× 102 1.2× 45 1.2× 16 768
Naoko Akiyama Japan 7 460 0.6× 215 0.5× 51 0.4× 106 1.2× 36 0.9× 15 644
Silvia Catellani Italy 16 662 0.8× 317 0.8× 57 0.5× 107 1.2× 24 0.6× 20 842
Sarah J. Flies United States 7 864 1.1× 773 1.9× 69 0.6× 150 1.7× 48 1.2× 7 1.2k
Jan Kubach Germany 9 798 1.0× 156 0.4× 56 0.5× 222 2.5× 62 1.6× 9 1.0k
Natalie Zimmerman United States 4 567 0.7× 282 0.7× 81 0.7× 86 1.0× 28 0.7× 4 736
Jolie G. Cullen Australia 7 681 0.8× 384 1.0× 99 0.8× 221 2.5× 34 0.9× 8 842
Jean‐Christophe Beltra United States 8 737 0.9× 595 1.5× 52 0.4× 195 2.2× 54 1.4× 9 962

Countries citing papers authored by Johan W. Molling

Since Specialization
Citations

This map shows the geographic impact of Johan W. Molling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan W. Molling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan W. Molling more than expected).

Fields of papers citing papers by Johan W. Molling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan W. Molling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan W. Molling. The network helps show where Johan W. Molling may publish in the future.

Co-authorship network of co-authors of Johan W. Molling

This figure shows the co-authorship network connecting the top 25 collaborators of Johan W. Molling. A scholar is included among the top collaborators of Johan W. Molling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan W. Molling. Johan W. Molling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Krijnen, Paul A.J., Jessica A. Sipkens, Johan W. Molling, et al.. (2010). Inhibition of Rho–ROCK signaling induces apoptotic and non-apoptotic PS exposure in cardiomyocytes via inhibition of flippase. Journal of Molecular and Cellular Cardiology. 49(5). 781–790. 25 indexed citations
2.
Grauer, Oliver, Johan W. Molling, Erik Bennink, et al.. (2008). TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas. The Journal of Immunology. 181(10). 6720–6729. 107 indexed citations
3.
Moreno, Marı́a, Johan W. Molling, Silvia von Mensdorff‐Pouilly, et al.. (2008). IFN-γ-Producing Human Invariant NKT Cells Promote Tumor-Associated Antigen-Specific Cytotoxic T Cell Responses. The Journal of Immunology. 181(4). 2446–2454. 46 indexed citations
4.
Molling, Johan W., Marı́a Moreno, Hans van Vliet, et al.. (2008). Invariant natural killer T cells and immunotherapy of cancer. Clinical Immunology. 129(2). 182–194. 28 indexed citations
5.
Moreno, Marı́a, Johan W. Molling, Silvia von Mensdorff‐Pouilly, et al.. (2008). In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells. Clinical Immunology. 129(1). 145–154. 9 indexed citations
6.
Molling, Johan W., Marı́a Moreno, Jan de Groot, et al.. (2008). Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases. Immunology Letters. 118(1). 36–43. 9 indexed citations
7.
Molling, Johan W., Tanja D. de Gruijl, Judith E. Glim, et al.. (2007). CD4+CD25hi regulatory T‐cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. International Journal of Cancer. 121(8). 1749–1755. 115 indexed citations
8.
Molling, Johan W., Marı́a Moreno, Hans van Vliet, et al.. (2007). Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. Journal of Immunological Methods. 322(1-2). 70–81. 15 indexed citations
9.
Molling, Johan W., J.A.E. Langius, Johannes A. Langendijk, et al.. (2007). Low Levels of Circulating Invariant Natural Killer T Cells Predict Poor Clinical Outcome in Patients With Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology. 25(7). 862–868. 164 indexed citations
10.
Vliet, Hans van, Marit G. A. van Vonderen, Johan W. Molling, et al.. (2006). Cutting Edge: Rapid Recovery of NKT Cells upon Institution of Highly Active Antiretroviral Therapy for HIV-1 Infection. The Journal of Immunology. 177(9). 5775–5778. 45 indexed citations
11.
Molling, Johan W., Wendy Kölgen, Hans van Vliet, et al.. (2005). Peripheral blood IFN‐γ‐secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. International Journal of Cancer. 116(1). 87–93. 190 indexed citations
12.
Vliet, Hans van, Johan W. Molling, B. Mary E. von Blomberg, et al.. (2004). The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clinical Immunology. 112(1). 8–23. 91 indexed citations
13.
Vliet, Hans van, Johan W. Molling, B. Mary E. von Blomberg, et al.. (2004). Circulating Vα24+Vβ11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. Clinical Immunology. 114(2). 183–189. 34 indexed citations
14.
Vliet, Hans van, Johan W. Molling, Nobusuke Nishi, et al.. (2003). Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.. PubMed. 63(14). 4101–6. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026